Navamedic Asa · OSL:NAVA
Navamedic Asa — Q1 2025 Earnings Presentation
20 slides from Navamedic Asa's earnings presentation, Apr 30, 2025
Slide 1: Q1 2025 Highlights and key figures
Q1 2025 Highlights and key figures 30 April 2025 Kathrine Gamborg Andreassen, CEO Lars Hjarrand. CFO
Slide 2: Navamedic in brief
Navamedic in brief A reliable supplier of high-quality pharma products addressing global health challenges Presence and sales Strong local market Portfolio tailored for Ambitious growth across the Nordics competence growing markets strategy going forward Strong local competence Thorough understandin
Slide 3: Strong start to the year and well-positioned for future growth
Q1 2025 Strong start to the year and well-positioned for future growth Highlights Q1: • Mysimba® 7% growth YOY REVENUE GROSS MARGIN EBITDA • High sales of antibiotics, +30% YOY Q1 132.0 MNOK 40.7 % 12.8 MNOK Subsequent events: 2025 +9.2% YoY 38.7 % in Q1 24 8.5 MNOK in Q1 24 • Renewed agreement for
Slide 4: Solid start to the year
Q1 2025 Solid start to the year + 6% 500 400 100 Revenue growth and EBITDA NOK million fluctuations from quarter to NOK million 300 quarter mainly due to seasonality and stock build- 200 50 up/down effects 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2023 2024 2025 Revenue ro
Slide 5: High-quality portfolio with several hero products
Our business areas High-quality portfolio with several hero products Hospital Prescription Drugs (RX) Consumer Health Antibiotics and Sold through pharmacies Sold through pharmacies Medical nutrition* Q1 25 Q1 25 33.1 revenue in revenue in 65.0 MNOK Q1 25 MNOK 33.9 revenue in YoY growth MNOK YoY gro
Slide 6: Prescription Drugs (RX): Growth across the portfolio
Prescription Drugs (RX) MYSIMBA® WHOLESALER VOLUME Vol. (units 000) Growth across the portfolio 200 The RX segment comprises Navamedic’s 150 prescription products 100 Q1 2025 revenue 50 65.0 MNOK 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 22 22 22 22 23 23 23 23 24 24 24 24 25 Iqvia data; Norway, Swed
Slide 7: Consumer Health: Steady development of main brands
Consumer Health Steady development of main brands The Consumer Health segment comprises Navamedic’s over-the-counter products, available to patients without a prescription Q1 2025 revenue 33.9 MNOK (Q1 2024: 33.8 MNOK) Highlights Coming up next Revenues of Modifast stable in the quarter • Out-licens
Slide 8: Hospital: Strong segment growth led by antibiotics portfolio
Hospital Strong segment growth led by antibiotics portfolio The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) Q1 2025 revenue 33.1 MNOK (Q1 2024: 28.8 MNOK) Highlights Coming up next Recent tender wi
Slide 9: Delivering on our strategy: Becoming a NOK billion revenue company
Delivering on our strategy Becoming a NOK 1 billion revenue company GROWTH BASED ON A STRONG FOUNDATION 1 Untapping the potential within existing products, categories and territories. Strengthening the core with a disciplined approach to portfolio management, including adding attractive new products
Slide 10: Financials
FINANCIALS @ Navamedic
Slide 11: Key consolidated profit and loss figures
In Q1 2025 revenues were 9.2% Financials above Q1 last year Key consolidated profit and loss figures Gross Profit came in at 40.7%, higher than the previous quarters and we expect to deliver higher operating Gross Margin in 2025 than 2024 (in NOK '1000) Q1 2025 Q1 2024 Year 2024 Operating revenues 1
Slide 12: Assets
Financials Assets Inventory increased since last quarter due to timing of large (in NOK '1000) 31.03.2025 31.03.2024 31.12.2024 orders Goodwill 162 285 157 057 159 051 Deferred tax assets 934 930 934 Cash level is mostly the Other intangible assets 91 819 95 839 92 561 combination of the net result
Slide 13: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.03.2025 31.03.2024 31.12.2024 Total equity 214 273 208 757 216 673 Equity ratio of 44%. Non-current interest-bearing borrowings 78 571 95 481 78 571 Note: The 2024 numbers reflect Non-current license liabilities 21 799 4 046 21 360 figures after co
Slide 14: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating Activities is mainly the result of (in NOK '1000) Q1 2025 Q1 2024 Year 2024 Profit Before Tax coupled with Net cash flow from operating activities 9 209 -5 563 39 354 changes in working capital items Net cash flow from invest
Slide 15: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook Strong start to the year and well positioned for future growth • Navamedic delivered NOK 132 million in revenue in Q1 2025, Ambition of building a representing a 9.2 % increase from 2024 • The growth was driven by the Prescription Drugs (RX) and Hospital NOK 1 billi
Slide 16: @ Navamedic
@ Navamedic
Slide 17: Want to know more?
Want to know more? Visit our website https://navamedic.com/ Follow us on LinkedIn #InvestInNavamedic Email infono@navamedic.com Navamedic’s Q2 2025 presentation will be held on August 14, 2025
Slide 18: Appendix
APPENDIX @ Navamedic
Slide 19: Basis for preparation and Definitions of Alternative Performance Measures
• Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pr
Slide 20: Copyright and disclaimer
• Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in a